Aggressive management may lead to fewer cardiac events after CAR T-cell therapy

Adults undergoing chimeric antigen receptor T-cell therapy are at low risk for major adverse cardiovascular events, according to data published in JACC: CardioOncology.
High occurrence of such events in prior retrospective studies indicated early intervention, aggressive treatment and close follow-up during cytokine release syndrome events as essential, according to researchers.
“CAR T-cell therapy appears safer than what was previously described, even as the prevalence of cardiovascular risk factors and diseases in our study was higher than in the general population,” Bénédicte

Adults undergoing chimeric antigen receptor T-cell therapy are at low risk for major adverse cardiovascular events, according to data published in JACC: CardioOncology.
High occurrence of such events in prior retrospective studies indicated early intervention, aggressive treatment and close follow-up during cytokine release syndrome events as essential, according to researchers.
“CAR T-cell therapy appears safer than what was previously described, even as the prevalence of cardiovascular risk factors and diseases in our study was higher than in the general population,” Bénédicte